Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Subscribe To Our Newsletter & Stay Updated
